These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34940634)

  • 1. Activity of Semi-Synthetic Mulinanes against MDR, Pre-XDR, and XDR Strains of
    Martínez-González MA; Peña-Rodríguez LM; Uc-Cachón AH; Bórquez J; Simirgiotis MJ; Barrios-García HB; Hernández-Pando R; Loyola LA; Areche C; Dzul-Beh AJ; Barrios-Payán JA; Mata-Espinosa D; Escalante-Erosa F; García-Sosa K; Molina-Salinas GM
    Metabolites; 2021 Dec; 11(12):. PubMed ID: 34940634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia.
    Shibabaw A; Gelaw B; Gebreyes W; Robinson R; Wang SH; Tessema B
    PLoS One; 2020; 15(2):e0229040. PubMed ID: 32053661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro bioevaluation and docking study of dihydrosphingosine and ethambutol analogues against sensitive and multi-drug resistant Mycobacterium tuberculosis.
    Linhares LA; Dos Santos Peixoto A; Correia de Sousa LA; Lucena Laet JP; da Silva Santos AC; Alves Pereira VR; Carneiro Neves MM; Ferreira LFGR; Hernandes MZ; de la Vega J; Pereira-Neves A; San Feliciano A; Olmo ED; Schindler HC; Montenegro LML
    Eur J Med Chem; 2023 Oct; 258():115579. PubMed ID: 37399709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Anti-Mycobacterial Activity Of Ag, ZnO, And Ag- ZnO Nanoparticles Against MDR- And XDR-
    Heidary M; Zaker Bostanabad S; Amini SM; Jafari A; Ghalami Nobar M; Ghodousi A; Kamalzadeh M; Darban-Sarokhalil D
    Infect Drug Resist; 2019; 12():3425-3435. PubMed ID: 31807033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.
    Cohen KA; Abeel T; Manson McGuire A; Desjardins CA; Munsamy V; Shea TP; Walker BJ; Bantubani N; Almeida DV; Alvarado L; Chapman SB; Mvelase NR; Duffy EY; Fitzgerald MG; Govender P; Gujja S; Hamilton S; Howarth C; Larimer JD; Maharaj K; Pearson MD; Priest ME; Zeng Q; Padayatchi N; Grosset J; Young SK; Wortman J; Mlisana KP; O'Donnell MR; Birren BW; Bishai WR; Pym AS; Earl AM
    PLoS Med; 2015 Sep; 12(9):e1001880. PubMed ID: 26418737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of (-)-deoxypergularinine, on its own and in combination with anti-tubercular drugs, against resistant strains of Mycobacterium tuberculosis.
    Nam KW; Jang WS; Jyoti MA; Kim S; Lee BE; Song HY
    Phytomedicine; 2016 May; 23(5):578-82. PubMed ID: 27064017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
    Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
    Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotyping and clinical characteristics of multidrug and extensively drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China.
    Yuan X; Zhang T; Kawakami K; Zhu J; Zheng W; Li H; Deng G; Tu S; Liu W
    BMC Infect Dis; 2013 Jul; 13():315. PubMed ID: 23849244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.
    Uc-Cachón AH; Borges-Argáez R; Said-Fernández S; Vargas-Villarreal J; González-Salazar F; Méndez-González M; Cáceres-Farfán M; Molina-Salinas GM
    Pulm Pharmacol Ther; 2014 Feb; 27(1):114-20. PubMed ID: 23968826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment efficacy of drug-resistant tuberculosis in Bashkortostan, Russia: A retrospective cohort study.
    Yunusbaeva M; Borodina L; Alekseev P; Davydov R; Yunusbaev U; Sharipov R; Bilalov F; Yunusbayev B
    Int J Infect Dis; 2019 Apr; 81():203-209. PubMed ID: 30794942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.
    Hu Y; Mathema B; Zhao Q; Zheng X; Li D; Jiang W; Wang W; Xu B
    Tuberculosis (Edinb); 2016 Mar; 97():18-25. PubMed ID: 26980491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.
    Velayati AA; Masjedi MR; Farnia P; Tabarsi P; Ghanavi J; ZiaZarifi AH; Hoffner SE
    Chest; 2009 Aug; 136(2):420-425. PubMed ID: 19349380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of collinin isolated from the leaves of Zanthoxylum schinifolium against multidrug- and extensively drug-resistant Mycobacterium tuberculosis.
    Kim S; Seo H; Mahmud HA; Islam MI; Lee BE; Cho ML; Song HY
    Phytomedicine; 2018 Jul; 46():104-110. PubMed ID: 30097109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of first and second-line drug resistance-associated mutations among resistant Mycobacterium tuberculosis clinical isolates from São Paulo, Brazil.
    Matsui T; Pinhata JMW; Rabello MCDS; Brandão AP; Ferrazoli L; Leão SC; Viana-Niero C; Oliveira RS
    Mem Inst Oswaldo Cruz; 2020; 115():e200055. PubMed ID: 32401997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region.
    Porwal C; Kaushik A; Makkar N; Banavaliker JN; Hanif M; Singla R; Bhatnagar AK; Behera D; Pande JN; Singh UB
    PLoS One; 2013; 8(2):e55299. PubMed ID: 23390524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redefining MDR-TB: Comparison of Mycobacterium tuberculosis clinical isolates from Russia and Taiwan.
    Jou R; Lee WT; Kulagina EV; Weng JY; Isakova AI; Lin WH; Antonova OV; Wu MH; Arslanbaeva LR; Tasi HY; Nosova EY; Zimenkov DV
    Infect Genet Evol; 2019 Aug; 72():141-146. PubMed ID: 30593924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Levels of Extensively Drug-resistant Tuberculosis among Multidrug Resistant Tuberculosis Isolates and Their Relationship to Risk Factors: Surveillance in Tehran, Iran; 2006 to 2014.
    Tasbiti AH; Yari S; Ghanei M; Shokrgozar MA; Fateh A; Bahrmand A
    Osong Public Health Res Perspect; 2017 Apr; 8(2):116-123. PubMed ID: 28540155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin).
    Mirza IA; Khan FA; Khan KA; Satti L; Ghafoor T; Fayyaz M
    J Coll Physicians Surg Pak; 2015 May; 25(5):337-41. PubMed ID: 26008658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.